O	0	5	Phase
O	6	9	III
O	10	15	trial
O	16	25	comparing
B-intervention	26	37	doxorubicin
I-intervention	38	42	plus
I-intervention	43	59	cyclophosphamide
O	60	64	with
B-control	65	74	docetaxel
I-control	75	79	plus
I-control	80	96	cyclophosphamide
O	97	99	as
O	100	108	adjuvant
O	109	116	therapy
O	117	120	for
O	121	129	operable
O	130	136	breast
O	137	143	cancer
O	143	144	.

O	145	148	The
O	149	160	combination
O	161	163	of
O	164	175	doxorubicin
O	176	179	and
O	180	196	cyclophosphamide
O	197	198	(
O	198	200	AC
O	200	201	)
O	202	204	is
O	205	206	a
O	207	215	standard
O	216	224	adjuvant
O	225	237	chemotherapy
O	238	245	regimen
O	245	246	.

O	247	254	Studies
O	255	257	of
O	258	267	docetaxel
O	268	271	and
O	272	288	cyclophosphamide
O	289	290	(
O	290	292	TC
O	292	293	)
O	294	296	in
O	297	307	metastatic
O	308	314	breast
O	315	321	cancer
O	322	323	(
O	323	326	MBC
O	326	327	)
O	328	334	showed
O	335	342	promise
O	343	345	in
O	346	349	MBC
O	349	350	.

O	351	353	In
O	354	358	1997
O	358	359	,
O	360	362	we
O	363	372	initiated
O	373	374	a
O	375	385	randomized
O	386	394	adjuvant
O	395	400	trial
O	401	403	of
O	404	406	TC
O	407	415	compared
O	416	420	with
O	421	429	standard
O	429	430	-
O	430	434	dose
O	435	437	AC
O	438	442	with
O	443	444	a
O	445	452	primary
O	453	456	end
O	457	462	point
O	463	465	of
B-outcome-Measure	466	473	disease
I-outcome-Measure	473	474	-
I-outcome-Measure	474	478	free
I-outcome-Measure	479	487	survival
I-outcome-Measure	488	489	(
I-outcome-Measure	489	492	DFS
I-outcome-Measure	492	493	)
O	493	494	.

O	495	503	Patients
O	504	508	were
O	509	517	eligible
O	518	520	if
O	521	525	they
O	526	529	had
B-eligibility	530	535	stage
I-eligibility	536	537	I
I-eligibility	538	540	to
I-eligibility	541	544	III
I-eligibility	545	553	operable
I-eligibility	554	562	invasive
I-eligibility	563	569	breast
I-eligibility	570	576	cancer
I-eligibility	577	581	with
I-eligibility	582	590	complete
I-eligibility	591	599	surgical
I-eligibility	600	608	excision
I-eligibility	609	611	of
I-eligibility	612	615	the
I-eligibility	616	623	primary
I-eligibility	624	629	tumor
O	629	630	.

O	631	638	Between
O	639	643	June
O	644	648	1997
O	649	652	and
O	653	661	December
O	662	666	1999
O	666	667	,
B-total-participants	668	669	1
I-total-participants	669	670	,
I-total-participants	670	673	016
O	674	682	patients
O	683	687	were
O	688	696	randomly
O	697	705	assigned
O	706	708	to
O	709	713	four
O	714	720	cycles
O	721	723	of
O	724	730	either
O	731	739	standard
O	739	740	-
O	740	744	dose
O	745	747	AC
O	748	749	(
O	749	751	60
O	752	755	and
O	756	759	600
O	760	762	mg
O	762	763	/
O	763	765	m2
O	765	766	,
O	767	779	respectively
O	779	780	;
O	781	782	n
O	783	784	=
B-intervention-participants	785	788	510
O	788	789	)
O	790	792	or
O	793	795	TC
O	796	797	(
O	797	799	75
O	800	803	and
O	804	807	600
O	808	810	mg
O	810	811	/
O	811	813	m2
O	813	814	,
O	815	827	respectively
O	827	828	;
O	829	830	n
O	831	832	=
B-control-participants	833	836	506
O	836	837	)
O	837	838	,
O	839	851	administered
O	852	865	intravenously
O	866	871	every
O	872	873	3
O	874	879	weeks
O	880	882	as
O	883	891	adjuvant
O	892	904	chemotherapy
O	904	905	.

O	906	915	Radiation
O	916	923	therapy
O	924	925	(
O	925	927	as
O	928	937	indicated
O	937	938	)
O	939	942	and
O	943	952	tamoxifen
O	952	953	,
O	954	957	for
O	958	966	patients
O	967	971	with
O	972	979	hormone
O	980	988	receptor
O	988	989	-
O	989	997	positive
O	998	1005	disease
O	1005	1006	,
O	1007	1011	were
O	1012	1024	administered
O	1025	1030	after
O	1031	1041	completion
O	1042	1044	of
O	1045	1057	chemotherapy
O	1057	1058	.

O	1059	1063	Both
O	1064	1073	treatment
O	1074	1080	groups
O	1081	1082	(
O	1082	1084	TC
O	1085	1088	and
O	1089	1091	AC
O	1091	1092	)
O	1093	1097	were
O	1098	1102	well
O	1103	1111	balanced
O	1112	1116	with
O	1117	1124	respect
O	1125	1127	to
O	1128	1133	major
O	1134	1144	prognostic
O	1145	1152	factors
O	1152	1153	.

O	1154	1162	Patients
O	1163	1167	were
O	1168	1176	observed
O	1177	1184	through
O	1185	1189	2005
O	1190	1193	for
O	1194	1195	a
O	1196	1202	median
O	1203	1205	of
O	1206	1207	5
O	1207	1208	.
O	1208	1209	5
O	1210	1215	years
O	1215	1216	.

O	1217	1219	At
O	1220	1221	5
O	1222	1227	years
O	1227	1228	,
B-outcome	1229	1232	DFS
I-outcome	1233	1237	rate
O	1238	1241	was
O	1242	1255	significantly
O	1256	1264	superior
O	1265	1268	for
O	1269	1271	TC
O	1272	1280	compared
O	1281	1285	with
O	1286	1288	AC
O	1289	1290	(
B-iv-bin-percent	1290	1292	86
I-iv-bin-percent	1292	1293	%
O	1294	1295	v
B-cv-bin-percent	1296	1298	80
I-cv-bin-percent	1298	1299	%
O	1299	1300	,
O	1301	1313	respectively
O	1313	1314	;
O	1315	1321	hazard
O	1322	1327	ratio
O	1328	1329	[
O	1329	1331	HR
O	1331	1332	]
O	1333	1334	=
O	1335	1336	0
O	1336	1337	.
O	1337	1339	67
O	1339	1340	;
O	1341	1343	95
O	1343	1344	%
O	1345	1347	CI
O	1347	1348	,
O	1349	1350	0
O	1350	1351	.
O	1351	1353	50
O	1354	1356	to
O	1357	1358	0
O	1358	1359	.
O	1359	1361	94
O	1361	1362	;
O	1363	1364	P
O	1365	1366	=
O	1367	1368	.
O	1368	1371	015
O	1371	1372	)
O	1372	1373	.

B-outcome	1374	1381	Overall
I-outcome	1382	1390	survival
I-outcome	1391	1396	rates
O	1397	1400	for
O	1401	1403	TC
O	1404	1407	and
O	1408	1410	AC
O	1411	1415	were
B-iv-bin-percent	1416	1418	90
I-iv-bin-percent	1418	1419	%
O	1420	1423	and
B-cv-bin-percent	1424	1426	87
I-cv-bin-percent	1426	1427	%
O	1427	1428	,
O	1429	1441	respectively
O	1442	1443	(
O	1443	1445	HR
O	1446	1447	=
O	1448	1449	0
O	1449	1450	.
O	1450	1452	76
O	1452	1453	;
O	1454	1456	95
O	1456	1457	%
O	1458	1460	CI
O	1460	1461	,
O	1462	1463	0
O	1463	1464	.
O	1464	1466	52
O	1467	1469	to
O	1470	1471	1
O	1471	1472	.
O	1472	1473	1
O	1473	1474	;
O	1475	1476	P
O	1477	1478	=
O	1479	1480	.
O	1480	1482	13
O	1482	1483	)
O	1483	1484	.

O	1485	1489	More
B-outcome	1490	1497	myalgia
I-outcome	1497	1498	,
I-outcome	1499	1509	arthralgia
I-outcome	1509	1510	,
I-outcome	1511	1516	edema
I-outcome	1516	1517	,
I-outcome	1518	1521	and
I-outcome	1522	1529	febrile
I-outcome	1530	1541	neutropenia
O	1542	1550	occurred
O	1551	1553	on
O	1554	1557	the
O	1558	1560	TC
O	1561	1564	arm
O	1564	1565	;
O	1566	1570	more
B-outcome	1571	1577	nausea
I-outcome	1578	1581	and
I-outcome	1582	1590	vomiting
O	1591	1599	occurred
O	1600	1602	on
O	1603	1606	the
O	1607	1609	AC
O	1610	1613	arm
O	1614	1616	as
O	1617	1621	well
O	1622	1624	as
O	1625	1628	one
O	1629	1637	incident
O	1638	1640	of
B-outcome	1641	1651	congestive
I-outcome	1652	1657	heart
I-outcome	1658	1665	failure
O	1665	1666	.

O	1667	1669	At
O	1670	1671	5
O	1672	1677	years
O	1677	1678	,
O	1679	1681	TC
O	1682	1685	was
O	1686	1696	associated
O	1697	1701	with
O	1702	1703	a
O	1704	1712	superior
O	1713	1716	DFS
O	1717	1720	and
O	1721	1722	a
O	1723	1732	different
O	1733	1741	toxicity
O	1742	1749	profile
O	1750	1758	compared
O	1759	1763	with
O	1764	1766	AC
O	1766	1767	.
